Ajay Nooka, MD MPH
Dr. Ajay Nooka is a Professor in the Department of Hematology and Medical Oncology at the Winship Cancer Institute of Emory University. He earned his medical degree from Andhra Medical College in India before relocating to the United States. He received a Masters’ in Public Health from the University of Texas School of Public Health in Houston, Texas and then completed his internship and residency at the Northeastern Ohio University College of Medicine, Ohio. He pursued a fellowship in Hematology and Oncology at Emory University School of Medicine in Atlanta, Georgia where he also served as Chief Fellow before he joined faculty. Board certified in Hematology and Medical oncology, Dr. Nooka is the Director of the Myeloma Program and Chairs the Myeloma Working Group at Department of Hematology & Oncology, Emory University and primarily focuses on multiple myeloma treatment and research. He is the Associate Director for Clinical Research at Winship Cancer Institute where he also serves as the Scientific Director of Data and Technology Applications. He is involved in numerous professional organizations, including the International Myeloma Working Group of International Myeloma Society, American Society of Clinical Oncology, the American Society of Hematology, and the American Society for Transplantation and Cellular Therapies. Dr. Nooka’s interests as a clinical investigator focuses on multiple myeloma and bone marrow transplant. His research interests include integrating molecular and clinical data to risk-stratify myeloma; and to evaluate newer myeloma therapeutic strategies aimed at prolonging survival in myeloma patients. In addition to leading several investigator-initiated and industry-sponsored clinical trials, he is a recipient of several awards and grants and has published more than 300 articles and abstracts in high quality peer-reviewed journals including New England Journal of Medicine, Journal of Clinical Oncology, Blood, Leukemia, Lancet Oncology, Blood Advances, Blood Cancer Journal and Cancer. He serves as a ‘Section Editor’ for the American Cancer Society journal Cancer and associate editor for Clinical Lymphoma, Myeloma and Leukemia, on serves on the editorial board of the American Journal of Clinical Oncology. He is an invited or ad hoc reviewer for several prestigious journals including Journal of Clinical Oncology, Lancet Oncology, Leukemia, Cancer, Blood Advances, Blood Cancer Journal, American Journal of Hematology, British Journal of Hematology, Bone Marrow Transplantation and Biology of Blood and Marrow Transplantation.
Financial relationships
-
Attribution:SelfType of financial relationship:Professional ServicesIneligible company:Janssen PharmacaeuticalsDate added:09/09/2023Date updated:09/09/2023Relationship end date:12/31/2024
-
Attribution:SelfType of financial relationship:Professional ServicesIneligible company:BMSDate added:09/09/2023Date updated:09/09/2023Relationship end date:12/31/2024
-
Attribution:SelfType of financial relationship:Professional ServicesIneligible company:SanofiDate added:09/09/2023Date updated:09/09/2023Relationship end date:12/31/2024
-
Attribution:SelfType of financial relationship:Professional ServicesIneligible company:PfizerDate added:09/09/2023Date updated:09/09/2023Relationship end date:12/31/2024
-
Attribution:SelfType of financial relationship:Professional ServicesIneligible company:Adaptive biotechnologyDate added:09/09/2023Date updated:09/09/2023Relationship end date:12/31/2024
-
Attribution:SelfType of financial relationship:Professional ServicesIneligible company:AmgenDate added:09/09/2023Date updated:09/09/2023Relationship end date:12/31/2024
-
Attribution:SelfType of financial relationship:Professional ServicesIneligible company:CellectarDate added:09/09/2023Date updated:09/09/2023Relationship end date:12/31/2024
-
Attribution:SelfType of financial relationship:Professional ServicesIneligible company:GSKDate added:09/09/2023Date updated:09/09/2023Relationship end date:12/31/2024
-
Attribution:SelfType of financial relationship:Professional ServicesIneligible company:ONK therapeuticsDate added:09/09/2023Date updated:09/09/2023Relationship end date:12/31/2024
-
Attribution:SelfType of financial relationship:Professional ServicesIneligible company:K36 therapeuticsDate added:09/09/2023Date updated:09/09/2023Relationship end date:12/31/2024